Optimizing GLP-1 Agonist Dosing

**Title: The Evolving Landscape of GLP-1 Agonist Dosing: A Comprehensive Overview** **Date: October 10, 2023** —…

‘A horrible episode’ | Atlanta man, doctors share warning of risk weight loss medications could pose – 11Alive.com WXIA

‘A horrible episode’ | Atlanta man, doctors share warning of risk weight loss medications could pose  11Alive.com…

NotCo’s New GLP-1 Booster Taps Into the Ozempic Craze – Minus the Side Effects – Green Queen Media

NotCo’s New GLP-1 Booster Taps Into the Ozempic Craze – Minus the Side Effects  Green Queen Media

GLP-1: Targeting Inflammation

**Title: The Promise of GLP-1 in Inflammation Therapy** **Date: October 5, 2023** — Key Takeaways GLP-1…

Clinical trial challenges in China: How a Sharp and ClinsChain pairing is breaking down barriers

While China has become a key country for global clinical trials, navigating regulatory complexities and ensuring…

Taiho outlays $1.14bn to acquire ADC specialist Araris

Taiho is turning its long-time ADC partner into a wholly owned subsidiary with the acquisition.

GLP-1 Agonists and Kidney Health: What You Need to Know

**Title: The Role of GLP-1 Agonists in Kidney Health: A Comprehensive Overview** **Date: October 5, 2023**…

GLP-1 and Lipid Metabolism: A Comprehensive Overview

**Title: The Emerging Role of GLP-1 in Lipid Metabolism: A Comprehensive Overview** **Glucagon-like peptide-1 (GLP-1) is…

Azurity acquires Covis Pharma from existing investors

Azurity Pharmaceuticals has acquired Covis Group from existing investors, making the latter a wholly owned subsidiary.

The cost of insurance cuts | Morning Newsletter – The Philadelphia Inquirer

The cost of insurance cuts | Morning Newsletter  The Philadelphia Inquirer